MARKET

EDSA

EDSA

Edesa Biotech Inc
NASDAQ
1.800
-0.280
-13.46%
Opening 12:08 11/13 EST
OPEN
1.960
PREV CLOSE
2.080
HIGH
2.020
LOW
1.790
VOLUME
301.26K
TURNOVER
--
52 WEEK HIGH
20.32
52 WEEK LOW
0.7200
MARKET CAP
24.31M
P/E (TTM)
-1.0638
1D
5D
1M
3M
1Y
5Y
1D
Healthcare Stocks Rally: EDSA And DCTH Jump 30%, VIR And IMVT Also Gain
NASDAQ · 3d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 4d ago
Edesa Biotech, Inc. Enters Into Collaboration and License Agreement with Kyorin Pharmaceutical and Terminates ATM Agreement
NASDAQ · 4d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 4d ago
Edesa Biotech Partners With KYORIN In Japan Deal Worth Up To $140 Million Plus Royalties; Stock Up
NASDAQ · 4d ago
Edesa Biotech Grants Kyorin Japanese Rights to Paridiprubart
TipRanks · 4d ago
Edesa and Kyorin announce collaboration and license agreement for paridiprubart
TipRanks · 4d ago
Edesa Biotech Enters Collaboration And License Agreement With Kyorin Pharmaceutical For Paridiprubart In Japan; Deal Valued At $140M+ With Potential Milestone Payments
Benzinga · 4d ago
More
About EDSA
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.

Webull offers Edesa Biotech Inc stock information, including NASDAQ: EDSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EDSA stock methods without spending real money on the virtual paper trading platform.